Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Shares Shorted: Short Interest Down 53.4% in September

Key Points

• Short interest fell 53.4% in September to 9,250 shares, representing 0.0% of shares outstanding and a days-to-cover ratio of 1.5.
• AAPG shares rose 2.8% to $15.16, but remain well below their 50-day and 200-day moving averages and near the stock’s one-year low of $14.45.
• Analysts maintain a favorable outlook, with a consensus “Buy” rating and a $43.67 price target; recent targets range from $33 to $48.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 9,250 shares, a decline of 53.4% from the September 15th total of 19,861 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average trading volume of 6,232 shares, the days-to-cover ratio is currently 1.5 days.

Ascentage Pharma Group International Trading Up 2.8%

Shares of NASDAQ:AAPG traded up $0.41 during trading on Tuesday, reaching $15.16. 1,235 shares of the company traded hands, compared to its average volume of 6,820. The firm has a fifty day simple moving average of $16.68 and a 200 day simple moving average of $19.27. Ascentage Pharma Group International has a 1-year low of $14.45 and a 1-year high of $37.50. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million during the quarter. Analysts predict that Ascentage Pharma Group International will post -2.42 EPS for the current fiscal year.

Analyst Ratings Changes

AAPG has been the topic of a number of recent analyst reports. Citizens Jmp assumed coverage on Ascentage Pharma Group International in a research report on Tuesday. They set a "market outperform" rating and a $35.00 target price on the stock. Citigroup assumed coverage on Ascentage Pharma Group International in a research report on Tuesday. They issued an "outperform" rating for the company. JPMorgan Chase & Co. dropped their price target on Ascentage Pharma Group International from $46.00 to $33.00 and set an "overweight" rating on the stock in a research note on Thursday, October 8th. Finally, BTIG Research restated a "buy" rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $43.67.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.